Interpharm Deferred Long Term Liab from 2010 to 2026
| IPAH Stock | USD 0 0.00 0.00% |
Deferred Long Term Liabilities | First Reported 2010-12-31 | Previous Quarter 554.3 K | Current Value 582 K | Quarterly Volatility 123 K |
Check Interpharm Holdings financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Interpharm Holdings' main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 9.1 M or Total Revenue of 56.6 M, as well as many indicators such as Price To Sales Ratio of 0.0105, Dividend Yield of 0.16 or PTB Ratio of 0.0696. Interpharm financial statements analysis is a perfect complement when working with Interpharm Holdings Valuation or Volatility modules.
Interpharm | Deferred Long Term Liab | Build AI portfolio with Interpharm Stock |
The Deferred Long Term Liab trend for Interpharm Holdings offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Interpharm Holdings is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Interpharm Holdings' Deferred Long Term Liab Growth Pattern
Below is the plot of the Deferred Long Term Liab of Interpharm Holdings over the last few years. It is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. Interpharm Holdings' Deferred Long Term Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Interpharm Holdings' overall financial position and show how it may be relating to other accounts over time.
| Deferred Long Term Liab | 10 Years Trend |
|
Deferred Long Term Liab |
| Timeline |
Interpharm Deferred Long Term Liab Regression Statistics
| Arithmetic Mean | 463,783 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 26.51 | |
| Mean Deviation | 54,563 | |
| Median | 482,000 | |
| Standard Deviation | 122,962 | |
| Sample Variance | 15.1B | |
| Range | 582K | |
| R-Value | 0.52 | |
| Mean Square Error | 11.8B | |
| R-Squared | 0.27 | |
| Significance | 0.03 | |
| Slope | 12,653 | |
| Total Sum of Squares | 241.9B |
Interpharm Deferred Long Term Liab History
About Interpharm Holdings Financial Statements
Investors use fundamental indicators, such as Interpharm Holdings' Deferred Long Term Liab, to determine how well the company is positioned to perform in the future. Although Interpharm Holdings' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Deferred Long Term Liabilities | 554.3 K | 582 K |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out the analysis of Interpharm Holdings Correlation against competitors. For more detail on how to invest in Interpharm Stock please use our How to Invest in Interpharm Holdings guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is there potential for Pharmaceuticals market expansion? Will Interpharm introduce new products? Factors like these will boost the valuation of Interpharm Holdings. Market participants price Interpharm higher when confident in its future expansion prospects. Understanding fair value requires weighing current performance against future potential. All the valuation information about Interpharm Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.09) | Revenue Per Share | Quarterly Revenue Growth (0.07) | Return On Assets | Return On Equity |
The market value of Interpharm Holdings is measured differently than its book value, which is the value of Interpharm that is recorded on the company's balance sheet. Investors also form their own opinion of Interpharm Holdings' value that differs from its market value or its book value, called intrinsic value, which is Interpharm Holdings' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Interpharm Holdings' market value can be influenced by many factors that don't directly affect Interpharm Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Interpharm Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if Interpharm Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Interpharm Holdings' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.